MDS-话题@MedSci

#MDS#

59篇内容 | 3421人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2251170, encodeId=390a22511e00a, content=<a href='/topic/show?id=9f061142249' target=_blank style='color:#2F92EE;'>#MDS#</a> <a href='/topic/show?id=d48b261e1a7' target=_blank style='color:#2F92EE;'>#低危#</a>, objectTitle=“低危”MDS：是否需要改变名称？, objectType=article, longId=862416, objectId=e515862416dd, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20250207/1738927032520_8538692.jpg, objectUrl=/article/show_article.do?id=e515862416dd, replyNumber=0, likeNumber=10, createdTime=2025-02-09, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=e515862416dd, moduleTitle=“低危”MDS：是否需要改变名称？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e515862416dd)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2243202, encodeId=1674224320214, content=<a href='/topic/show?id=9f061142249' target=_blank style='color:#2F92EE;'>#MDS#</a> <a href='/topic/show?id=fab3101964cd' target=_blank style='color:#2F92EE;'>#骨髓增生异常综合征#</a>, objectTitle=【AJH】维奈克拉联合去甲基化药物治疗初治较高危MDS的中国真实世界研究, objectType=article, longId=855703, objectId=242b855e039a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240509/1715223995977_5579292.jpg, objectUrl=/article/show_article.do?id=242b855e039a, replyNumber=0, likeNumber=0, createdTime=2024-12-18, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=242b855e039a, moduleTitle=【AJH】维奈克拉联合去甲基化药物治疗初治较高危MDS的中国真实世界研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=242b855e039a)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2242490, encodeId=367d22424909d, content=<a href='/topic/show?id=9f061142249' target=_blank style='color:#2F92EE;'>#MDS#</a> <a href='/topic/show?id=850849e666e' target=_blank style='color:#2F92EE;'>#异基因造血干细胞移植#</a>, objectTitle=老年MDS的异基因造血干细胞移植：考虑因素和挑战, objectType=article, longId=855332, objectId=7996855332d3, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202301017/1697523836362_2570354.jpg, objectUrl=/article/show_article.do?id=7996855332d3, replyNumber=0, likeNumber=28, createdTime=2024-12-15, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=7996855332d3, moduleTitle=老年MDS的异基因造血干细胞移植：考虑因素和挑战, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7996855332d3)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2239586, encodeId=e569223958620, content=<a href='/topic/show?id=9f061142249' target=_blank style='color:#2F92EE;'>#MDS#</a> <a href='/topic/show?id=2d4c4140296' target=_blank style='color:#2F92EE;'>#地西他滨#</a> <a href='/topic/show?id=329c2e376fa' target=_blank style='color:#2F92EE;'>#信迪利单抗#</a>, objectTitle=【JITC】黄晓军院士牵头信迪利单抗联合地西他滨治疗较高危初治MDS的II期研究结果, objectType=article, longId=852913, objectId=6cc18529136a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2022224/1645674156506_5552845.jpg, objectUrl=/article/show_article.do?id=6cc18529136a, replyNumber=0, likeNumber=33, createdTime=2024-11-27, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6cc18529136a, moduleTitle=【JITC】黄晓军院士牵头信迪利单抗联合地西他滨治疗较高危初治MDS的II期研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6cc18529136a)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2236890, encodeId=2623223689033, content=<a href='/topic/show?id=9f061142249' target=_blank style='color:#2F92EE;'>#MDS#</a> <a href='/topic/show?id=fab3101964cd' target=_blank style='color:#2F92EE;'>#骨髓增生异常综合征#</a>, objectTitle=【Haematologica】综述：MDS的诊断, objectType=article, longId=851043, objectId=49d585104315, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20241113/1731477719555_8538692.jpg, objectUrl=/article/show_article.do?id=49d585104315, replyNumber=0, likeNumber=0, createdTime=2024-11-14, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=江苏省, moduleDTOList=[ModuleDTO(moduleId=49d585104315, moduleTitle=【Haematologica】综述：MDS的诊断, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=49d585104315)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2235902, encodeId=e2882235902f4, content=<a href='/topic/show?id=9f061142249' target=_blank style='color:#2F92EE;'>#MDS#</a> <a href='/topic/show?id=fab3101964cd' target=_blank style='color:#2F92EE;'>#骨髓增生异常综合征#</a>, objectTitle=【Haematologica】较低危MDS的治疗原则, objectType=article, longId=850215, objectId=b12a8502156e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20220801/1659342224826_8252897.webp, objectUrl=/article/show_article.do?id=b12a8502156e, replyNumber=0, likeNumber=71, createdTime=2024-11-08, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b12a8502156e, moduleTitle=【Haematologica】较低危MDS的治疗原则, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b12a8502156e)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2233790, encodeId=d6c12233e9060, content=<a href='/topic/show?id=9f061142249' target=_blank style='color:#2F92EE;'>#MDS#</a> <a href='/topic/show?id=fab3101964cd' target=_blank style='color:#2F92EE;'>#骨髓增生异常综合征#</a>, objectTitle=【柳叶刀血液学】数据驱动的MDS统一分类系统：国际MDS联盟一致性分析, objectType=article, longId=848912, objectId=3b55848912ed, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240711/1720670560286_5579292.jpg, objectUrl=/article/show_article.do?id=3b55848912ed, replyNumber=0, likeNumber=84, createdTime=2024-10-28, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=3b55848912ed, moduleTitle=【柳叶刀血液学】数据驱动的MDS统一分类系统：国际MDS联盟一致性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b55848912ed)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2222300, encodeId=b3022222300fa, content=<a href='/topic/show?id=9f061142249' target=_blank style='color:#2F92EE;'>#MDS#</a> <a href='/topic/show?id=518761566e4' target=_blank style='color:#2F92EE;'>#来那度胺#</a> <a href='/topic/show?id=f33110964155' target=_blank style='color:#2F92EE;'>#骨髓增生异常肿瘤#</a>, objectTitle=【Leukemia】del(5q) MDS患者来那度胺治疗12个月后或可实现停药, objectType=article, longId=840385, objectId=e2988403856c, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240802/1722585125228_8538692.png, objectUrl=/article/show_article.do?id=e2988403856c, replyNumber=0, likeNumber=95, createdTime=2024-08-25, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=e2988403856c, moduleTitle=【Leukemia】del(5q) MDS患者来那度胺治疗12个月后或可实现停药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e2988403856c)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2220228, encodeId=42a92220228b2, content=<a href='/topic/show?id=9f061142249' target=_blank style='color:#2F92EE;'>#MDS#</a> <a href='/topic/show?id=fab3101964cd' target=_blank style='color:#2F92EE;'>#骨髓增生异常综合征#</a>, objectTitle=【Leukemia】在大样本MDS中验证原始细胞计数的独立预后性能, objectType=article, longId=838951, objectId=ffca838951a5, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240808/1723083734259_8538692.jpg, objectUrl=/article/show_article.do?id=ffca838951a5, replyNumber=0, likeNumber=65, createdTime=2024-08-15, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=ffca838951a5, moduleTitle=【Leukemia】在大样本MDS中验证原始细胞计数的独立预后性能, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ffca838951a5)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2218731, encodeId=90f32218e3191, content=<a href='/topic/show?id=9f061142249' target=_blank style='color:#2F92EE;'>#MDS#</a> <a href='/topic/show?id=b2d849e64c4' target=_blank style='color:#2F92EE;'>#异基因移植#</a>, objectTitle=JCO：肿瘤科大查房系列：MDS异基因移植的时机和决策模型, objectType=article, longId=837631, objectId=b10b83e63160, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240731/1722408726164_8538692.jpg, objectUrl=/article/show_article.do?id=b10b83e63160, replyNumber=0, likeNumber=109, createdTime=2024-08-06, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b10b83e63160, moduleTitle=JCO：肿瘤科大查房系列：MDS异基因移植的时机和决策模型, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b10b83e63160)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2205544, encodeId=2f2922055441e, content=<a href='/topic/show?id=9f061142249' target=_blank style='color:#2F92EE;'>#MDS#</a> <a href='/topic/show?id=fab3101964cd' target=_blank style='color:#2F92EE;'>#骨髓增生异常综合征#</a>, objectTitle=年仅10岁，血三系减少，不是再障，骨髓检查揭开谜底, objectType=article, longId=826554, objectId=7eb282655488, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240519/1716120380731_5579292.jpg, objectUrl=/article/show_article.do?id=7eb282655488, replyNumber=0, likeNumber=98, createdTime=2024-05-19, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=7eb282655488, moduleTitle=年仅10岁，血三系减少，不是再障，骨髓检查揭开谜底, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7eb282655488)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1842832, encodeId=dc4c1842832cc, content=<a href='/topic/show?id=9f061142249' target=_blank style='color:#2F92EE;'>#MDS#</a>, objectTitle=刘菁解读：MDS 统一帕金森病评定量表(MDS-UPDRS）, objectType=article, longId=734900, objectId=5dfbe3490044, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5dfbe3490044, replyNumber=0, likeNumber=141, createdTime=2022-10-27, rootId=0, userName=d830372, userId=80a244, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5dfbe3490044, moduleTitle=刘菁解读：MDS 统一帕金森病评定量表(MDS-UPDRS）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5dfbe3490044)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1842831, encodeId=20c8184283102, content=<a href='/topic/show?id=9f061142249' target=_blank style='color:#2F92EE;'>#MDS#</a>, objectTitle=J Clin Oncol：HCT后采用Eprenetapopt+阿扎胞苷维持治疗TP53突变型AML和MDS的效益, objectType=article, longId=734319, objectId=1531e34319fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1531e34319fe, replyNumber=0, likeNumber=129, createdTime=2023-02-23, rootId=0, userName=d830372, userId=80a244, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1531e34319fe, moduleTitle=J Clin Oncol：HCT后采用Eprenetapopt+阿扎胞苷维持治疗TP53突变型AML和MDS的效益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1531e34319fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1842829, encodeId=f4dc18428297f, content=<a href='/topic/show?id=9f061142249' target=_blank style='color:#2F92EE;'>#MDS#</a>, objectTitle= Leuk Res：多西帕他钠 (DSTAT)，一种 CXCL12/CXCR4 抑制剂，与阿扎胞苷联合用于治疗低甲基化剂难治性 AML 和 MDS, objectType=article, longId=294099, objectId=a0a42940993e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a0a42940993e, replyNumber=0, likeNumber=127, createdTime=2022-06-20, rootId=0, userName=d830372, userId=80a244, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a0a42940993e, moduleTitle= Leuk Res：多西帕他钠 (DSTAT)，一种 CXCL12/CXCR4 抑制剂，与阿扎胞苷联合用于治疗低甲基化剂难治性 AML 和 MDS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a0a42940993e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1842830, encodeId=d5321842830f0, content=<a href='/topic/show?id=9f061142249' target=_blank style='color:#2F92EE;'>#MDS#</a>, objectTitle=FDA解除Magrolimab治疗MDS和AML的临床研究的限制, objectType=article, longId=724488, objectId=eb97e24488ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb97e24488ca, replyNumber=0, likeNumber=108, createdTime=2023-02-17, rootId=0, userName=d830372, userId=80a244, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb97e24488ca, moduleTitle=FDA解除Magrolimab治疗MDS和AML的临床研究的限制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb97e24488ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1842827, encodeId=0466184282eea, content=<a href='/topic/show?id=9f061142249' target=_blank style='color:#2F92EE;'>#MDS#</a>, objectTitle=J Clin Oncol：5-aza+HSCT可显著提高MDS老年患者的生存率, objectType=article, longId=214570, objectId=899e2145e0f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=899e2145e0f2, replyNumber=0, likeNumber=93, createdTime=2022-04-15, rootId=0, userName=d830372, userId=80a244, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=899e2145e0f2, moduleTitle=J Clin Oncol：5-aza+HSCT可显著提高MDS老年患者的生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=899e2145e0f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1842828, encodeId=1fe4184282867, content=<a href='/topic/show?id=9f061142249' target=_blank style='color:#2F92EE;'>#MDS#</a>, objectTitle=Lancet Haematol：Venetoclax联合强化化疗治疗AML或高危MDS的效果, objectType=article, longId=215478, objectId=74912154e866, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74912154e866, replyNumber=0, likeNumber=143, createdTime=2021-11-14, rootId=0, userName=d830372, userId=80a244, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74912154e866, moduleTitle=Lancet Haematol：Venetoclax联合强化化疗治疗AML或高危MDS的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74912154e866)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1842823, encodeId=d7b318428237e, content=<a href='/topic/show?id=9f061142249' target=_blank style='color:#2F92EE;'>#MDS#</a>, objectTitle=J Clin Oncol：强化调理方案不能改善高危型AML/MDS老年患者allo-HSCT后的预后, objectType=article, longId=205037, objectId=941420503ec4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=941420503ec4, replyNumber=0, likeNumber=116, createdTime=2021-11-11, rootId=0, userName=d830372, userId=80a244, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=941420503ec4, moduleTitle=J Clin Oncol：强化调理方案不能改善高危型AML/MDS老年患者allo-HSCT后的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=941420503ec4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1842822, encodeId=abda18428226d, content=<a href='/topic/show?id=9f061142249' target=_blank style='color:#2F92EE;'>#MDS#</a>, objectTitle=Clin Cancer Res：急慢性移植物抗MDS对异基因造血细胞移植后的长期预后的影响, objectType=article, longId=201703, objectId=cdb2201e0302, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cdb2201e0302, replyNumber=0, likeNumber=135, createdTime=2021-04-18, rootId=0, userName=d830372, userId=80a244, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cdb2201e0302, moduleTitle=Clin Cancer Res：急慢性移植物抗MDS对异基因造血细胞移植后的长期预后的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cdb2201e0302)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1842820, encodeId=097d18428203b, content=<a href='/topic/show?id=9f061142249' target=_blank style='color:#2F92EE;'>#MDS#</a>, objectTitle=Blood：机器学习揭示MDS基因型和形态学特征的相关性, objectType=article, longId=201339, objectId=5de1201339a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5de1201339a1, replyNumber=0, likeNumber=113, createdTime=2021-06-16, rootId=0, userName=d830372, userId=80a244, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5de1201339a1, moduleTitle=Blood：机器学习揭示MDS基因型和形态学特征的相关性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5de1201339a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

MDS

2020-05-29

梅斯管理员

#MDS# #低危#

“低危”MDS：是否需要改变名称？

2025-02-09发表于陕西省

梅斯管理员

#MDS# #骨髓增生异常综合征#

【AJH】维奈克拉联合去甲基化药物治疗初治较高危MDS的中国真实世界研究

2024-12-18发表于陕西省

梅斯管理员

#MDS# #异基因造血干细胞移植#

老年MDS的异基因造血干细胞移植：考虑因素和挑战

2024-12-15发表于陕西省

梅斯管理员

#MDS# #地西他滨# #信迪利单抗#

【JITC】黄晓军院士牵头信迪利单抗联合地西他滨治疗较高危初治MDS的II期研究结果

2024-11-27

梅斯管理员

#MDS# #骨髓增生异常综合征#

【Haematologica】综述：MDS的诊断

2024-11-14发表于江苏省

梅斯管理员

#MDS# #骨髓增生异常综合征#

【Haematologica】较低危MDS的治疗原则

2024-11-08发表于上海

梅斯管理员

#MDS# #骨髓增生异常综合征#

【柳叶刀血液学】数据驱动的MDS统一分类系统：国际MDS联盟一致性分析

2024-10-28发表于上海

梅斯管理员

#MDS# #来那度胺# #骨髓增生异常肿瘤#

【Leukemia】del(5q) MDS患者来那度胺治疗12个月后或可实现停药

2024-08-25发表于上海

梅斯管理员

#MDS# #骨髓增生异常综合征#

【Leukemia】在大样本MDS中验证原始细胞计数的独立预后性能

2024-08-15发表于上海

梅斯管理员

#MDS# #异基因移植#

JCO：肿瘤科大查房系列：MDS异基因移植的时机和决策模型

2024-08-06发表于上海

梅斯管理员

#MDS# #骨髓增生异常综合征#

年仅10岁，血三系减少，不是再障，骨髓检查揭开谜底

2024-05-19发表于上海

d830372

#MDS#

刘菁解读：MDS 统一帕金森病评定量表(MDS-UPDRS）

2022-10-27

d830372

#MDS#

J Clin Oncol：HCT后采用Eprenetapopt+阿扎胞苷维持治疗TP53突变型AML和MDS的效益

2023-02-23

d830372

#MDS#

Leuk Res：多西帕他钠 (DSTAT)，一种 CXCL12/CXCR4 抑制剂，与阿扎胞苷联合用于治疗低甲基化剂难治性 AML 和 MDS

2022-06-20

d830372

#MDS#

FDA解除Magrolimab治疗MDS和AML的临床研究的限制

2023-02-17

d830372

#MDS#

J Clin Oncol：5-aza+HSCT可显著提高MDS老年患者的生存率

2022-04-15

d830372

#MDS#

Lancet Haematol：Venetoclax联合强化化疗治疗AML或高危MDS的效果

2021-11-14

d830372

#MDS#

J Clin Oncol：强化调理方案不能改善高危型AML/MDS老年患者allo-HSCT后的预后

2021-11-11

d830372

#MDS#

Clin Cancer Res：急慢性移植物抗MDS对异基因造血细胞移植后的长期预后的影响

2021-04-18

d830372

#MDS#

Blood：机器学习揭示MDS基因型和形态学特征的相关性

2021-06-16